Fujifilm, Dr. Reddy’s End Generics JV in Japan

Fujifilm Corp. and Dr. Reddy’s Laboratories Ltd. have terminated the Memorandum of Understanding (MoU) to establish a joint venture in Japan for a generic drugs business.
 
The MoU, signed in July 2011, involved conducting detailed studies on the establishment of a joint venture for developing and manufacturing generic drugs in Japan. The two companies plan to explore other partnership opportunities such as API development and manufacturing, contract R&D and manufacturing, and the development and marketing of “super-generics.”
 
GV Prasad, chairman and chief executive officer, Dr. Reddy’s, said, “Unfortunately, we will not be able to partner with Fujifilm specifically for generic formulations business in Japan. However, I want to reinforce our commitment towards a planned entry into Japan to bring affordable and innovative drugs to more patients worldwide.”
 
Takatoshi Ishikawa, Fujifilm’s director corporate vice president and general manager of its Pharmaceutical Products Division, said, “In the long term we will be focusing more on priority fields such as new drugs in cancer field, more value-added super-generic, and bio-related business by using our core technologies: analysis technologies, original nanotechnology, and high reliability and high quality manufacturing technologies. Meanwhile, we will continue future collaboration with Dr. Reddy’s in other fields.”